Pharmaceuticals · Cleaning Validation
Cleaning Validation Consulting for Pharmaceutical Manufacturing
The short answer
Cleaning validation demonstrates that a documented cleaning procedure consistently reduces residues to scientifically justified limits on shared equipment. The technical work is rarely the swabbing; it is the limits rationale, the recovery data supporting the analytical method and the worst-case selection that ties the whole program together.
01
Why this matters
- Shared-facility cross-contamination is one of the few compliance issues that can result in patient harm and product recall from a single failure.
- Limits based only on 1/1000 of a therapeutic dose or 10 ppm are increasingly difficult to defend without a health-based exposure assessment.
- A cleaning program that cannot be executed on the shift schedule will be shortcut, and the deviation appears months later as a residue result nobody can explain.
02
Applicable regulations and standards
- 21 CFR 211.67
- Equipment cleaning and maintenance, including written procedures and records.
- EMA guideline on shared facilities
- Health-based exposure limits (PDE) as the basis for cleaning limits in multi-product facilities.
- ICH Q9
- Risk-based worst-case product and equipment grouping.
- 21 CFR 211.182
- Equipment cleaning and use logs.
03
What our consultants actually do
- Develop the cleaning validation master plan, including product and equipment grouping with a written worst-case rationale
- Establish limits using health-based exposure data and translate PDE values into swab and rinse acceptance criteria
- Design recovery studies, coupon studies and sampling location maps based on actual equipment geometry
- Review analytical methods for specificity and sensitivity at the required limit, including TOC suitability
- Address campaign length, dirty and clean hold times, and manual versus automated cleaning variability
- Investigate cleaning failures and build the monitoring program that keeps the validated state current
04
Across the product lifecycle
01 / DEVELOP
Solubility, degradation and residue behaviour understood before procedures are written.
02 / SCALE
Equipment train and worst-case surface area reassessed at commercial scale.
03 / TRANSFER
Cleaning procedures and limits revisited for the receiving site's equipment.
04 / VALIDATE
Protocol execution with defensible sampling and recovery-corrected results.
05 / MANUFACTURE
Cleaning records, hold times and campaign controls executed as validated.
06 / MAINTAIN
Periodic monitoring, new-product impact assessment and re-evaluation of limits.
05
Problems we are usually called about
- Recovery factors never applied to reported results
- Swab locations chosen for accessibility rather than worst case
- Visually clean used as the sole criterion on equipment where residue would not be visible
- No assessment when a new, more potent product enters the facility
- Dirty hold time validated at 24 hours while production routinely runs longer
06
Typical deliverables
- Cleaning validation master plan and grouping rationale
- Health-based exposure limit assessment and derived acceptance criteria
- Recovery study protocols and reports
- Cleaning validation protocols, sampling diagrams and executed reports
- Ongoing monitoring and new-product impact assessment procedure
07
Frequently asked
- Do we need health-based exposure limits for every product?
- For multi-product facilities, a toxicological assessment establishing a permitted daily exposure is the current expectation for setting carryover limits. Dedicated equipment trains may be handled differently, but the rationale still needs to be written down.
- Is visual inspection acceptable as a cleaning criterion?
- Visual inspection is a useful additional control and can support a program when the visible residue limit has been determined and qualified for the inspectors performing it. It is not sufficient on its own for equipment where residues at the acceptance limit would not be visible.
- How often should cleaning validation be reassessed?
- At minimum when a new product is introduced, when the cleaning procedure, agent or equipment changes, and on a periodic review interval defined in the master plan. Routine monitoring results should feed that review.
08
References
More for pharmaceuticals
cGMP, validation and manufacturing quality support for drug products.
- Process ValidationProcess validation for a drug product is a three-stage lifecycle: design the process and its control strategy, qualify commercial-scale performance, and then verify that the process stays in control for as long as it is used.
- cGMP ConsultingcGMP consulting for a drug manufacturer means making 21 CFR Parts 210 and 211 operable in your facility — with procedures your staff can follow, records that reconstruct what happened and a quality unit with the authority to act.
- Technology TransferTechnology transfer succeeds or fails on what the receiving site is given: process understanding, not just a batch record.
- Quality SystemsA pharmaceutical quality system is the set of connected processes — documents, changes, deviations, CAPA, training, release, review — that keep product decisions defensible.
- IND CMC SupportSponsors filing an IND usually need two things at once: CMC content for the application and a quality system capable of overseeing clinical manufacturing.
- NDA Manufacturing SupportThis is the site-side companion to an NDA filing: making sure the validated process, the control strategy and the records at the manufacturing site match what the application says, and that the people there can explain it during a pre-approval inspection..
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.